Lactobacillus reuteri CCFM1040 stands out from traditional strains in providing targeted respiratory benefits primarily due to its clinical patent validation, which helps support the management of respiratory allergy symptoms. Furthermore, featuring a high concentration of 100 billion CFU/g and advanced 5-layer microencapsulation technology, it is designed to ensure high strain viability and effective targeted delivery. This combination of clinical validation, high viability, and advanced delivery makes it an ideal ingredient for B2B brand owners developing premium anti-allergy products.
This targeted respiratory support is backed by rigorous scientific research and clinical data. Clinical studies indicate that L. reuteri CCFM1040 helps support the management of asthma symptoms and provides significant support for individuals with allergic rhinitis. By helping to modulate immune balance, it helps reduce excessive sensitivity in the respiratory tract, providing tangible health benefits for those with respiratory allergy concerns. This targeted clinical validation differentiates it from many traditional probiotics.
Furthermore, advanced manufacturing processes and flexible supply chain services provide strong support for product development. The high concentration of 100 billion CFU/g helps ensure that each serving delivers robust health benefits, while the 5-layer microencapsulation technology acts as a protective shield, offering excellent stability during storage and helping to enhance in vivo delivery. Additionally, the product is manufactured under strict GMP certification to ensure high-quality and safety standards. We offer flexible packaging options, including 1 kg, 5 kg, or customized sizes, helping brand owners easily create high-quality, differentiated anti-allergy health products.